What is the recommended treatment for primary Epstein‑Barr virus infection?

Treatment of Primary Epstein-Barr Virus Infection

Primary EBV infection (infectious mononucleosis) in immunocompetent individuals requires supportive care only—antiviral drugs are not recommended and have no proven clinical benefit.

Immunocompetent Patients with Primary EBV Infection

Standard Management

For typical infectious mononucleosis in otherwise healthy individuals, treatment is entirely supportive:

• Rest, hydration, and symptomatic relief
• Antiviral drugs (acyclovir, ganciclovir, foscarnet) are NOT recommended 1, 2, 3
• While antivirals can suppress oropharyngeal viral shedding, they have minimal to no effect on clinical symptoms 2, 3
• The virus exists in a latent state in infected B cells where it does not express the viral thymidine kinase needed for antiviral drug activation 1

Role of Corticosteroids

Corticosteroids should be reserved for specific severe complications only 4:

• Upper airway obstruction (most clear indication)
• Severe immune-mediated thrombocytopenia or hemolytic anemia
• Not recommended for routine uncomplicated infectious mononucleosis

Important caveat: The combination of acyclovir plus prednisolone showed dramatic clinical improvement in fulminant mononucleosis cases (9/11 patients improved within 72 hours) 2, but this represents a rare, life-threatening presentation requiring hospitalization—not typical infectious mononucleosis.

Post-Transplant or Immunocompromised Patients

The treatment paradigm is completely different in immunocompromised patients, particularly after hematopoietic stem cell transplantation:

Preemptive Therapy (EBV DNAemia without symptoms)

Rituximab is the primary treatment 1:

• Dose: 375 mg/m² IV once weekly
• Duration: 1-4 doses until EBV DNA negativity
• Combined with reduction of immunosuppression when possible (except in severe GVHD) 1
• Monitor EBV viral load to guide therapy duration
• Antiviral drugs remain ineffective even in this setting 1

Treatment of EBV-PTLD (Post-Transplant Lymphoproliferative Disorder)

First-line therapy 1:

1. Rituximab 375 mg/m² weekly for up to 4 doses (achieves ~70% response rate)
2. Reduce immunosuppression when feasible
3. EBV-specific cytotoxic T-lymphocytes (CTLs) if available

Second-line therapy (after rituximab failure) 1:

1. Cellular therapy (EBV-specific CTLs or donor lymphocyte infusion)
2. Chemotherapy ± rituximab
3. Surgery, IVIG, interferon, and antiviral agents are NOT recommended 1

CNS EBV Disease

For central nervous system involvement 1:

• Rituximab ± chemotherapy (high-dose methotrexate/cytarabine protocols)
• Consider intrathecal rituximab
• EBV-specific T-cell therapy or radiotherapy as alternatives

Key Clinical Pitfalls

1. Do not prescribe antivirals for typical infectious mononucleosis—they waste resources and provide no benefit despite in vitro activity 1, 2, 3

2. Do not use corticosteroids routinely—reserve for life-threatening complications like airway obstruction 4

3. Recognize the distinction: Primary EBV infection in healthy individuals is self-limited; EBV disease in transplant recipients is potentially fatal and requires aggressive intervention 1

4. In transplant patients, do not delay rituximab while waiting for biopsy confirmation if clinical suspicion is high—PTLD can progress rapidly to multi-organ failure 1

5. Geographic and population differences exist: CAEBV disease (chronic active EBV) is more recognized in Asia and represents a distinct T/NK-cell lymphoproliferative disorder requiring hematopoietic stem cell transplantation for cure 5